The Netherlands Heart Foundation awards Linxis and academic partners in the fight against PH

Through a first-in-human PET tracer study, the project aims to demonstrate Fibrobody disposition in the fibrotic vasculature of patients with pulmonary hypertension (PH). Moreover, the consortium will develop novel Fibrobody-Drug-Conjugates to reverse the fibrotic vascular remodeling that takes place in PH.

PH is a progressive, deadly condition presenting in 1% of the global population, often at a relatively young age. Diagnostic tools are lacking and treatment options few. The use of Fibrobodies in PH could lead to a personalized medicine approach without invasive diagnostic procedures, and will create innovative pharmaceutical opportunities contributing to better PH treatment.

Linxis, with its unique concept and company philosophy, has received a warm welcome from the researchers within the PHAEDRA-IMPACT consortium. The consortium is funded by the Dutch Cardiovascular Alliance, and is a collaboration between the Amsterdam UMC, Leiden UMC, Twente University and Maastricht University. For more than 8 years, PHAEDRA IMPACT has played an important role in the global search for new diagnostic and therapeutic tools in the field of PH. The collaboration with LinXis has the potential to generate a major breakthrough in this disease area.

The collaboration project is co-funded by the PPP Allowance made available by Health~Holland, Top Sector Life Sciences & Health, to stimulate public-private partnerships.